Kamada (KMDA) Cash from Operations Growth (1y) (2013 - 2026)
Kamada (KMDA) Cash from Operations Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 425.00% |
| 10 | Kamada | 405.25 Mn | 332.11 Mn | 19.12 Mn | 43.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.27% |
| Dec 31, 2025 | -27.24% |
| Sep 30, 2025 | -53.11% |
| Jun 30, 2025 | -42.56% |
| Mar 31, 2025 | -150.29% |
| Dec 31, 2024 | 70.18% |
| Sep 30, 2024 | 2,311.83% |
| Jun 30, 2024 | 668.04% |
| Mar 31, 2024 | 35,876.92% |
| Dec 31, 2023 | 90,525.93% |
| Sep 30, 2023 | 16,669.85% |
| Jun 30, 2023 | -83.30% |
| Mar 31, 2023 | -100.05% |
| Dec 31, 2022 | 235.68% |
| Sep 30, 2022 | 100.21% |
| Jun 30, 2022 | 431.92% |
| Mar 31, 2022 | 159.99% |
| Dec 31, 2021 | -100.04% |
| Sep 30, 2021 | -212.17% |
| Jun 30, 2021 | -130.78% |